A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Inclusion Criteria: * Male or female patients, ≥ 18 years of age, able to understand and give written informed consent * Histologically or cytologically confirmed colorectal adenocarcinoma * Stage IV (metastatic) disease * Previously treated with at least one prior irinotecan-containing regimen for colorectal cancer * Adequate performance status (ECOG 0 or 1) (Appendix 1) * Expected survival ≥ 6 months * CEA plasma levels \> 5 ng/mL * Measurable disease by CT or MRI, but with no single lesion measuring more than 10.0 cm * At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities * Adequate hematology without ongoing transfusional support (hemoglobin \> 8 g/dL, ANC ≥ 1,500 per mm3, platelets \> 100,000 per mm3) * Adequate renal and hepatic function (creatinine ≤ 1.5 x IULN, bilirubin within normal limits, AST and ALT ≤ 3.0 x IULN or 5 x IULN if know liver metastases) * Otherwise, all acute toxicity at study entry ≤ Grade 1 by NCI CTC v4.0, or recovered to baseline Exclusion Criteria: * Women who are pregnant or lactating. * Women of childbearing potential and fertile men unwilling to use effective contraception during study until conclusion of 12-week post-treatment evaluation period. * Patients with Gilbert's disease or known CNS metastatic disease. However, patients with CNS metastases who are asymptomatic and have completed a course of therapy are eligible for the study provided that they are clinically stable for 1 month prior to entry as defined as: (1) no evidence of new enlarging CNS metastasis, (2) off steroids or on a stable dose of steroids. * Patients with CEA plasma levels \> 1000 ng/mL must be approved in advance by the Sponsor. * Patients with active ≥ Grade 3 anorexia, nausea or vomiting, and/or signs of intestinal obstruction. * Patients with non-melanoma skin cancer or carcinoma in situ of the cervix are eligible, while patients with other prior malignancies must have had at least a 3-year disease-free interval, or are deemed at low risk for recurrence by his/her treating physician. * Patients known to be HIV positive, hepatitis B positive, or hepatitis C positive. * Known history of unstable angina, MI, or CHF present within 6 months or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy. * Known history of clinically significant active COPD, or other moderate-to-severe chronic respiratory illness present within 6 months. * Infection requiring intravenous antibiotic use within 1 week. * Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.